Get the Stockscreener App
0.2491
2.02%
0.0017
Onconetix Inc stock is traded at $0.2491, with a volume of 493.15K.
It is up +2.02% in the last 24 hours and down -58.56% over the past month.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
See More
Previous Close:
$0.2474
Open:
$0.275
24h Volume:
493.15K
Relative Volume:
0.06
Market Cap:
$3.60M
Revenue:
-
Net Income/Loss:
$-53.12M
P/E Ratio:
-0.00229
EPS:
-108.8
Net Cash Flow:
$-15.86M
1W Performance:
-36.90%
1M Performance:
-58.56%
6M Performance:
-95.10%
1Y Performance:
-96.57%
1-Day Range:
$0.2459
$0.275
1-Week Range:
$0.2456
$0.38
52-Week Range:
$0.2456
$21.40
Onconetix Inc Stock (ONCO) Company Profile
Name
Onconetix Inc
Sector
Industry
Phone
513-620-4101
Address
201 E. FIFTH STREET, CINCINNATI
Compare ONCO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCO
Onconetix Inc
|
0.2465 | 3.60M | 0 | -53.12M | -15.86M | -108.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.83 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.93 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.15 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.59 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Onconetix Inc Stock (ONCO) Latest News
Onconetix taps industry veteran as executive chairman amid CEO resignation - Cincinnati Business Courier
Onconetix names new executive chairman, appoints board member By Investing.com - Investing.com Australia
Onconetix names new executive chairman, appoints board member - Investing.com India
Onconetix Announces Leadership Changes and New Appointments - TipRanks
Onconetix Says Ralph Schiess Resigns As Interim CEO And Chief Science Officer -February 28, 2025 at 05:35 pm EST - Marketscreener.com
Onconetix secures new financing, appoints auditor, sees executive exit By Investing.com - Investing.com South Africa
Onconetix secures new financing, appoints auditor, sees executive exit - Investing.com
Onconetix Announces Promissory Note Agreement with Keystone - TipRanks
Investing in Onconetix Inc (ONCO) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Onconetix Inc (ONCO) Stock: A Year of Decreases and Increases - The InvestChronicle
Daily Market Movement: Onconetix Inc (ONCO) Sees a 11.91 Increase, Closing at 0.61 - The Dwinnex
Onconetix files to sell 50M shares of common stock for holders - MSN
Stock market today: Allakos dropped by 76.37% whereas Onconetix jumped by 77.10% in early trading - Business Upturn
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Onconetix faces Nasdaq delisting over share price rule - MSN
Onconetix faces Nasdaq delisting over share price rule By Investing.com - Investing.com Nigeria
Onconetix settles with IQVIA, adjusts accounts payable - MSN
Onconetix settles with IQVIA, adjusts accounts payable By Investing.com - Investing.com Canada
Pre-market Movers: ONCO, EYEN, SGMO, VSTM... - RTTNews
Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews
US Stocks Open Higher; House Prices Increase In October - Benzinga
ONCO Stock Plummets to 52-Week Low at $0.37 Amid Market Struggles By Investing.com - Investing.com South Africa
Onconetix files overdue quarterly report, addresses Nasdaq notice By Investing.com - Investing.com South Africa
Onconetix files overdue quarterly report, addresses Nasdaq notice - Investing.com
Onconetix, Inc. Announces Receipt of Notice from Nasdaq - GlobeNewswire
Onconetix Resolves Nasdaq Compliance Issue After Late Q3 Filing - StockTitan
ONCO stock touches 52-week low at $0.58 amid market challenges - Investing.com India
Onconetix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Onconetix Inc. (ONCO) reports earnings - Quartz
Onconetix amends forbearance agreement with Veru Inc. - Investing.com
ONCO Stock Hits 52-Week Low at $0.6 Amid Market Challenges - Investing.com Nigeria
ONCO stock touches 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa
ONCO stock touches 52-week low at $0.99 amid market challenges - Investing.com
SEC Form 424B4 filed by Onconetix Inc. - Quantisnow
Zurcher Kantonalbank's Strategic Acquisition of Onconetix Inc Sh - GuruFocus.com
ONCO stock touches 52-week low at $2.8 amid market challenges By Investing.com - Investing.com South Africa
ONCO stock touches 52-week low at $2.8 amid market challenges - Investing.com Canada
Onconetix, Inc. (NASDAQ:ONCO) Sees Large Decline in Short Interest - MarketBeat
Onconetix announces change in certifying accountant - Investing.com India
Onconetix announces change in certifying accountant By Investing.com - Investing.com South Africa
Onconetix, Inc. (NASDAQ:ONCO) Short Interest Update - MarketBeat
Onconetix Inc Stock (ONCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.91%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):